Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (NASDAQ: DTIL) reported Q1 2026 results and operational progress, highlighting $125.8 million in cash on March 31, 2026 and advancement of two wholly owned in vivo programs: PBGENE-HBV (ongoing ELIMINATE-B trial; late-breaking EASL poster) and PBGENE-DMD (FDA IND cleared, Fast Track, first site activated).
Q1 revenue was $10.8 million; net loss was $18.4 million, or $(0.75) per share. Company expects cash runway to support key data milestones through 2028.
Precision BioSciences (Nasdaq: DTIL) said it will publish first quarter 2026 financial results and provide a business update on May 5, 2026. The company is a clinical‑stage gene editing firm using its proprietary ARCUS platform to develop in vivo therapies for high‑unmet‑need diseases.
Precision BioSciences (Nasdaq: DTIL) activated Arkansas Children’s Hospital as the first clinical trial site and opened patient screening and enrollment for PBGENE-DMD in the Phase 1/2 FUNCTION-DMD study on April 29, 2026. PBGENE-DMD targets DMD mutations between exons 45 and 55 and will assess safety, tolerability, dystrophin expression, and functional outcomes in ambulatory patients.
Arkansas Children’s is a PPMD-certified Duchenne Care Center and an MDA Care Center; additional sites are being activated to expand enrollment.
iECURE (NASDAQ:DTIL) will present preliminary clinical data for ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency at ASGCT (May 11-15, 2026) and SIMD (May 17-20, 2026).
Oral data cover the first three dose cohorts (n=7) and report a decreased rate of hyperammonemic crises. A SIMD poster shows one-year post-treatment data for the first infant who achieved a complete clinical response with sustained discontinuation of standard-of-care therapies.
Precision BioSciences (Nasdaq: DTIL) announced an oral presentation of new preclinical PBGENE-DMD data at the ASGCT 2026 Annual Meeting, May 11-15 in Boston.
The abstract reports efficacy in early-juvenile mice and builds on prior updates showing durable functional improvement in a humanized DMD mouse model. Presentation: May 14, 2026 at 8:45 a.m. ET; Presenter: Adam Michler Ph.D., DMD Research Lead; Session: Emerging molecular therapeutic strategies for muscular dystrophies.
Precision BioSciences (Nasdaq: DTIL) announced that on April 20, 2026 the Compensation Committee approved an inducement award of 7,094 restricted stock units (RSUs) for a newly hired employee under its 2021 Inducement Award Plan.
The RSUs vest in substantially equal annual installments on each of the first three anniversaries of the employee’s start date, subject to continued service.
Precision BioSciences (NASDAQ: DTIL) will present late-breaking biopsy data for PBGENE-HBV at EASL Congress 2026, showing evidence of elimination and inactivation of cccDNA in liver biopsies from the ongoing Phase 1 ELIMINATE-B trial.
The poster (LB26-51656 / LBP-043) will be presented by Man-Fung Yuen on May 27, 2026 at 8:30 CEST in Barcelona.
Precision BioSciences (Nasdaq: DTIL) received Clinical Trial Application approvals to expand the global ELIMINATE-B trial into France and Romania, adding European sites to existing locations in the UK, Moldova, New Zealand, Hong Kong and the US. Site initiation activities are underway and initial patient screening is expected in Q2 2026.
The expansion aims to support continued patient enrollment and clinical execution of PBGENE-HBV, a gene editing therapy designed to eliminate cccDNA, as the company advances the ELIMINATE-B trial.
Precision BioSciences (Nasdaq: DTIL) will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 9:30am ET. The presentation is virtual and will be webcast. A replay will be posted in the company's Investors section under Events and Presentations after the event.
If investors or analysts wish to request a meeting, contact your Needham representative.
iECURE (NASDAQ:DTIL) announced that ECUR-506, its investigational in vivo targeted gene insertion therapy for neonatal-onset ornithine transcarbamylase (OTC) deficiency, was selected for the FDA’s CMC Development and Readiness Pilot (CDRP) program.
Participation enables more frequent FDA engagement on CMC strategy ahead of a potential BLA, complements prior RMAT and Fast Track designations, and follows encouraging OTC-HOPE clinical data including a complete response in the first treated infant. Additional trial data is expected in H1 2026.